Physician profile
Jeffrey Strossner
NPI 1902880214
$1,862.98
in general payments reported to CMS, 2019-2025
21 companies · $678 in 2025
The $678 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $102 · 2021: $203 · 2022: $162 · 2023: $296 · 2024: $322 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $424.76 | 2021-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $251.47 | 2023-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $245.70 | 2020-2025 | Total30, Precision7, Clareon |
| Biotissue Holdings INC. | $139.07 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $131.25 | 2019-2023 | |
| Rxsight INC | $97.99 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.03 | 2020-2021 | |
| Coopervision INC. | $59.83 | 2019-2025 | Biofinity Contact Lens, Clariti Contact Lens |
| Shire North American Group INC | $59.69 | 2019 | |
| Allergan, INC. | $56.24 | 2020-2022 | |
| Amgen INC. | $52.32 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $45.74 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $43.04 | 2021 | |
| Harrow Eye, LLC | $41.25 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $25.28 | 2024 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.41 | 2024 | Ultomiris |
| Dompe US, INC. | $20.33 | 2025 | Oxervate |
| Abbvie INC. | $19.31 | 2023 | Vuity, Lumigan |
| Thea Pharma INC. | $18.50 | 2024 | Iyuzeh |
| Oyster Point Pharma, INC. | $18.44 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Strossner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.